...
首页> 外文期刊>Molecular Endocrinology >Misfolding Ectodomain Mutations of the Lutropin Receptor Increase Efficacy of Hormone Stimulation
【24h】

Misfolding Ectodomain Mutations of the Lutropin Receptor Increase Efficacy of Hormone Stimulation

机译:Lutropin受体的错误折叠Ectodomain突变增加激素刺激的功效。

获取原文
           

摘要

We demonstrate 2 novel mutations of the LHCGR, each homozygous, in a 46,XY patient with severe Leydig cell hypoplasia. One is a mutation in the signal peptide (p.Gln18_Leu19ins9; referred to here as SP) that results in an alteration of the coding sequence of the N terminus of the mature mutant receptor. The other mutation (p.G71R) is also within the ectodomain. Similar to many other inactivating mutations, the cell surface expression of recombinant human LHR(SP,G71R) is greatly reduced due to intracellular retention. However, we made the unusual discovery that the intrinsic efficacy for agonist-stimulated cAMP in the reduced numbers of receptors on the cell surface was greatly increased relative to the same low number of cell surface wild-type receptor. Remarkably, this appears to be a general attribute of misfolding mutations in the ectodomains, but not serpentine domains, of the gonadotropin receptors. These findings suggest that there must be a common, shared mechanism by which disparate mutations in the ectodomain that cause misfolding and therefore reduced cell surface expression concomitantly confer increased agonist efficacy to those receptor mutants on the cell surface. Our data further suggest that, due to their increased agonist efficacy, extremely small changes in cell surface expression of misfolded ectodomain mutants cause larger than expected alterations in the cellular response to agonist. Therefore, for inactivating LHCGR mutations causing ectodomain misfolding, the numbers of cell surface mutant receptors on fetal Leydig cells of 46,XY individuals exert a more exquisite effect on the relative severity of the clinical phenotypes than already appreciated.
机译:我们在严重的Leydig细胞发育不全的46,XY患者中证明了 LHCGR 的两个新突变,每个突变都是纯合的。一种是信号肽中的突变(p.Gln18_Leu19ins9;在此称为SP),该突变导致成熟突变体受体N末端编码序列的改变。另一个突变(p.G71R)也在胞外域内。与许多其他失活突变相似,由于细胞内保留,重组人LHR(SP,G71R)的细胞表面表达大大降低。但是,我们做出了一个不寻常的发现,即相对于相同数量的细胞表面野生型受体,激动剂刺激的cAMP在减少的细胞表面受体数量上的内在功效大大提高。值得注意的是,这似乎是促性腺激素受体的胞外域而非蛇形域中错误折叠突变的一般属性。这些发现表明,必须存在共同的共同机制,通过胞外域中的不同突变导致错误折叠并因此降低细胞表面表达,从而同时赋予细胞表面那些受体突变体激动剂功效。我们的数据进一步表明,由于激动剂功效的提高,错折叠的胞外域突变体在细胞表面表达的极小变化导致细胞对激动剂反应的改变大于预期。因此,为了使导致胞外域错误折叠的 LHCGR 突变失活,46,XY个体的胎儿Leydig细胞上的细胞表面突变受体数量对临床表型的相对严重程度的影响要比已经认识到的更为精确。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号